EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Bruno Sangro iD, Peter R Galle, Robin Kate Kelley iD, Chaiyut Charoentum, Enrico N De Toni iD, Yurii Ostapenko, Jeong Heo iD, Ann-Lii Cheng iD, Andrea Wilson Woods iD, Charu Gupta, Jayne Abraham, Carrie L McCoy und 4 weitere

Journal of Clinical Oncology · 10.08.2024 · 42 (23) · 2790-2799

DOI: 10.1200/jco.23.01462 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2024. Verfasst von Bruno Sangro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Patient Reported Outcome Measures, Antibodies, Monoclonal. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In the phase III HIMALAYA study (ClinicalTrials.gov identifier: NCT03298451 ) in unresectable hepatocellular carcinoma (uHCC), the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen significantly improved overall survival versus sorafenib, and durvalumab monotherapy was noninferior to sorafenib. Patient-reported outcomes (PROs), a secondary outcome from HIMALAYA, are reported here. METHODS Participants were randomly assigned to receive STRIDE, durvalumab, or sorafenib. PROs were assessed (preplanned secondary outcome) using the European Organization for Research and Treatment of Cancer 30-item Quality of Life Questionnaire and the 18-item HCC module. Time to deterioration (TTD), change from baseline and improvement rate in global health status/quality of life (GHS/QoL), functioning, and disease-related symptoms were analyzed. RESULTS In total, 1,171 participants were randomly assigned to STRIDE (n = 393), durvalumab (n = 389), or sorafenib (n = 389) and were evaluable for PRO assessments. Across treatment arms, compliance rates for PROs were >77% at baseline and >70% overall. Baseline scores were comparable across treatment arms. TTD in GHS/QoL, physical functioning, fatigue, appetite loss, and abdominal pain was numerically longer for both STRIDE and durvalumab versus sorafenib. Clinically meaningful deterioration in PROs was not observed in any treatment arm. However, TTD in nausea and abdominal swelling was numerically longer for STRIDE versus sorafenib, and the likelihood of clinically meaningful improvement in GHS/QoL, role, emotional and social functioning, and disease-related symptoms was greater with STRIDE and durvalumab versus sorafenib. PROs with STRIDE and durvalumab were generally similar. CONCLUSION Compared with sorafenib, STRIDE and durvalumab were associated with clinically meaningful, patient-centered GHS/QoL, functioning, and symptom benefits in people with uHCC. These findings support the benefits of the STRIDE regimen compared with sorafenib for a diverse population reflective of the global uHCC population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPatient Reported Outcome MeasuresAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsQuality of LifeHumansMaleFemaleMiddle AgedAgedSorafenibAdult

Substanzen

durvalumabtremelimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedSorafenib

Autor:innen und Institutionen

  • Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
  • University Medical Center, Mainz, Germany.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
  • Department of Internal Medicine, Faculty of Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
  • Department of Minimally Invasive and Endoscopic Surgery, Intervention Radiology, National Cancer Institute, Kiev, Ukraine.

ORCID-Profile: Bruno Sangro, Robin Kate Kelley, Enrico N De Toni, Jeong Heo, Ann-Lii Cheng, Andrea Wilson Woods, Arndt Vogel, Ghassan K Abou-Alfa

Förderung

  • NCI NIH HHS

Zitieren

APA

Sangro, B., Galle, P. R., Kelley, R. K., Charoentum, C., De Toni, E. N., Ostapenko, Y., Heo, J., Cheng, A. L., Wilson Woods, A., Gupta, C., Abraham, J., McCoy, C. L., Patel, N., Negro, A., Vogel, A., & Abou-Alfa, G. K. (2024). Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 42(23), 2790-2799. https://doi.org/10.1200/jco.23.01462

Vancouver

Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, et al. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology. 2024;42(23):2790-2799. doi:10.1200/jco.23.01462

BibTeX
@article{Sangro2024,
  author = {Sangro, Bruno and Galle, Peter R and Kelley, Robin Kate and Charoentum, Chaiyut and De Toni, Enrico N and Ostapenko, Yurii and Heo, Jeong and Cheng, Ann-Lii and Wilson Woods, Andrea and Gupta, Charu and Abraham, Jayne and McCoy, Carrie L and Patel, Nikunj and Negro, Alejandra and Vogel, Arndt and Abou-Alfa, Ghassan K},
  title = {Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {23},
  pages = {2790--2799},
  doi = {10.1200/jco.23.01462}
}
Kostenlos starten →